

# Erwin DREESEN

MSc, PharmD, PhD | Academic pharmacometrician



## PERSONAL INFORMATION

Date of birth February 7, 1986

Place of birth Maaseik, Belgium

 Belgian

 Married, no children

 Baron D'Eynattenstraat 4 box 0616, 3000 Leuven, Belgium

 +32 497 65 84 47

 erwin.dreesen@kuleuven.be



## CURRENT POSITION

### Postdoctoral research fellow

Funded by the Research Foundation – Flanders (FWO)

Application I2X9420N

Clinical Pharmacology and Pharmacotherapy Unit

Department of Pharmaceutical and Pharmacological Sciences

Supervisor: Prof. Dr Isabel Spriet

*Pharmacometric models for improved therapeutic drug monitoring of ceftriaxone, posaconazole and infliximab*

KU Leuven, Leuven, Belgium

October 2019 – present

## PREVIOUS POSITIONS

### Postdoctoral research fellow

Therapeutic and Diagnostic Antibodies Unit

Department of Pharmaceutical and Pharmacological Sciences

Head of Unit: Prof. Dr Paul Declerck

KU Leuven, Leuven, Belgium

June 2019 – September 2019

### Doctoral research fellow

Therapeutic and Diagnostic Antibodies Unit

Department of Pharmaceutical and Pharmacological Sciences

Promotor: Prof. Dr Ann Gils

*Pharmacometric models to improve therapeutic drug monitoring of monoclonal antibodies in the treatment of inflammatory bowel diseases*

Defence: 7 May 2019

KU Leuven, Leuven, Belgium

September 2014 – May 2019

### Adjunct pharmacist

De Lindeboom Pharmacy

Steenokkerzeel, Belgium

August 2012 – August 2014

### Pharmacist

Markt Maaseik Pharmacy & Schoofs Pharmacy

Maaseik & Meeuwen, Belgium

July 2012 – August 2012

## EDUCATION

### **Master of Statistics | Biostatistics (distance learning)**

with greatest distinction (1<sup>st</sup> year), 2<sup>nd</sup> year ongoing

Faculty of Sciences

UHasselt, Hasselt, Belgium

September 2017 – present

### **Master of Science | Pharmaceutical Care**

with great distinction

Faculty of Pharmaceutical Sciences

KU Leuven, Leuven, Belgium

September 2009 – June 2012

*Thesis: Pharmacotherapeutic aspects of Thelin® (sitaxentan sodium) in pulmonary arterial hypertension*

### **Master of Biomedical Sciences | Research**

with great distinction

Faculty of Medicine

KU Leuven, Leuven, Belgium

September 2004 – June 2009

*Thesis: Characterisation of the ecto-phosphodiesterase NPP5*

## COUNCIL AND COMMITTEE MEMBERSHIPS

- + Member of the Ethics Committee of the University Hospitals and University of Leuven | 2021 – present
- + Expert for the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) | 2020 – present
- + Member of the Pharmacometrics Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) | 2019 – present
- + Substitute member of the Council of the Faculty of Pharmaceutical Sciences, KU Leuven | 2017 – 2019
- + Member of the Council of the Faculty of Pharmaceutical Sciences, KU Leuven | 2014 – 2017
- + Member of the organising committee of the European university consortium for pharmaceutical sciences (ULLA) Summer School | 2017
- + Member of the organising committee of the European university consortium for pharmaceutical sciences (ULLA) Workshop | 2016
- + Participant in LE STUDIUM Monitoring of monoclonal Antibodies Group in Europe (MAGE) for inflammatory diseases Research Consortium (CS10-I-MAGE), Tours, France | 2015 – 2017

## EDITORIAL ACTIVITIES

- + Member of the Editorial Board of Journal of Crohn's and Colitis | Jul 2021 – Jun 2024
- + Review Editor and Guest Editor for Frontiers journal | 2019 – present
- + Topic Editor of Pharmaceutics | 2020 – present
- + Over 60 peer reviews for over 20 journals

## HONOURS AND AWARDS

- + **FWO Travel Grant for long stay abroad**, 2020, Uppsala, Sweden
- + **ECCO Best Investigator-Initiated Study Abstract Award**, Congress of the European Crohn's and Colitis Organisation, 2019, Copenhagen, Denmark
- + **FWO Travel Grant**, Digestive Disease Week, 2018, Washington, DC, USA
- + **UEG National Scholar Award**, United European Gastroenterology Week, 2015, Barcelona, Spain
- + **UEG Travel Grant (Basic Science)**, United European Gastroenterology Week, 2015, Barcelona, Spain
- + **KU Leuven First Contact Initiatives**, Research stay at François-Rabelais University PATCH Team, 2015, Tours, France (Prof. Dr Denis Mulleman)

## EDUCATIONAL ACTIVITIES

- + **Co-promotor** of doctoral student Omar Elkayal, Faculty of Pharmaceutical Sciences, KU Leuven | 2020 – *present*
- + **Co-promotor** of doctoral student Zhigang Wang, Faculty of Pharmaceutical Sciences, KU Leuven | 2020 – *present*
- + **Co-promotor** of doctoral student Wannee Kantasiripitak, Faculty of Pharmaceutical Sciences, KU Leuven | 2019 – *present*
- + **Lecturer** of Advanced Clinical Drug Development with a Focus on Applied Pharmacometrics course, Faculty of Pharmaceutical Sciences, KU Leuven | 2019 – *present*
- + **Invited lecturer** on precision dosing in Pharmaceutical Biotechnology course, Faculty of Pharmaceutical Sciences, KU Leuven | 2019
- + Member of jury Master Theses, Faculty of Pharmaceutical Sciences, KU Leuven | 2014 – *present*
- + Supervisor of predoctoral student Omar Elkayal, Faculty of Pharmaceutical Sciences, KU Leuven | 2020
- + Supervisor of predoctoral student Zhigang Wang, Faculty of Pharmaceutical Sciences, KU Leuven | 2020
- + Supervisor of predoctoral student Wannee Kantasiripitak, Faculty of Pharmaceutical Sciences, KU Leuven | 2018 – 2019
- + **Assistant** of Pharmaceutical Biotechnology: Seminars, Faculty of Pharmaceutical Sciences, KU Leuven | 2017 – 2019
- + Assistant of Biopharmaceutical Research: Exercises II – Practical Exercises: Instrumental Analysis, Faculty of Pharmaceutical Sciences, KU Leuven | 2015 – 2019
- + Assistant of Advanced Non-clinical Drug Development Including Applied Pharmacometrics, Faculty of Pharmaceutical Sciences, KU Leuven | 2017 – 2018
- + Assistant of Pharmaceutical Biotechnology – Practice Exercises, Faculty of Pharmaceutical Sciences, KU Leuven | 2014 – 2017
- + Supervisor of Master Thesis titled “*Explaining variability in infliximab exposure in patients with inflammatory bowel disease: suggestions for treatment optimisation*” of Eliana Peeters, Master of Bioinformatics, KU Leuven | 2015 – 2016
- + Moderator of Drug Interactions workshops, Faculty of Pharmaceutical Sciences, KU Leuven | 2014 – 2015

## INVITED LECTURES

- [1] at the Inflammatory Bowel Disease Delta Day organised by UZ Leuven, Erasmus MC Rotterdam, and Leiden UMC, titled '*eHEALTH and state of the Art*', 22 January 2021, Online
- [2] at the Therapeutic Drug Monitoring Symposium of the Pharmacology meeting organised by the British Pharmacological Society, titled '*Therapeutic drug monitoring of biological therapies in chronic inflammatory diseases*', 14 December 2020, Online
- [3] at the 14<sup>th</sup> Clinical Pharmacy Symposium organised by KU Leuven, titled "*Therapeutic drug monitoring of antimicrobial drugs*" (webinar), 12 November 2020, Online
- [4] at the Educational Pharmacometrics Summer Symposium '*Pharmacometrics: from here to where?*' organised by the ISoP Student Community and the ISoP Clinical Pharmacometrics SIG, 9 June 2020, Ljubljana, Slovenia (postponed to 22 June 2021 due to COVID-19)
- [5] at the Therapeutic Drug Monitoring Workshop '*Therapeutic drug monitoring of antimicrobials, antiepileptic drugs and biologics*' organised by Hospital Universitari de Bellvitge-IDIBELL and the School of Pharmacy, Universitat de Barcelona, 18 March 2020, Barcelona, Spain (postponed due to COVID-19)
- [6] at the 17<sup>th</sup> International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, titled '*Is there a place for therapeutic drug monitoring of drugs other than infliximab for inducing response in patients with inflammatory bowel diseases?*', 23 September 2019, Foz do Iguassu, Brazil
- [7] at the Gastroenterology Centre of Excellence meeting organised by UZ Leuven and Janssen, on therapeutic drug monitoring, 6 September 2019, Leuven, Belgium
- [8] at the Pharmacometrics Network Benelux Meeting, titled '*Pharmacometric models to improve therapeutic drug monitoring of monoclonal antibodies in the treatment of inflammatory bowel diseases*', 9 May 2019, Niel, Belgium
- [9] at the postgraduate course of the Flemish Association of Hospital Pharmacists, titled '*Pharmacokinetics and therapeutic drug monitoring of monoclonal antibodies*', 6 September 2016, Belgium

## INTERNATIONAL EXPERIENCE

- + Visiting postdoctoral research fellow at Radboud UMC Applied Pharmacometrics Research Group, Nijmegen, The Netherlands | 2021; *planned*
- + Visiting postdoctoral research fellow at Uppsala University Pharmacometrics Research Group, Uppsala, Sweden | August 2020 – February 2021
- + Uppsala Pharmacometrics Summer School: Covariate model building + PKPD modelling of continuous and categorical data, Uppsala University, Uppsala, Sweden | 7 – 18 August 2017
- + Visiting PhD student at François-Rabelais University PATCH Team, Tours, France (Prof. Dr Denis Mulleman) | January – May 2015

## PERSONAL SKILLS

### Software

Microsoft Windows	●●●●●	Berkeley-Madonna	●●●●○
macOS	●●●●●	Simulo	●●●○●
Microsoft Office	●●●●●	Prism	●●●●●
LaTeX	●●●○●	R	●●●●●
NONMEM	●●●●●	SAS	●●●●○
Monolix	●●●●○	SPSS	●●●○●

### Languages

Dutch	●●●●●	English	●●●●●	French	●●●○●
-------	-------	---------	-------	--------	-------

## INTERESTS

### Volunteering

- + Raising 12.000+ euro as a participant of 'Mediclowns New York Marathon 2016' to raise awareness and funds to support Mediclowns (<http://www.mediclowns.be>) February 2016 – November 2016

### Interests

- + Running, hiking, traveling

## SCIENTIFIC PUBLICATIONS IN INTERNATIONAL PEER-REVIEWED JOURNALS

*\* Five key publications*

- [1] Wang Z, Dreesen E. Therapeutic drug monitoring of anti-tumor necrosis factor agents: lessons learned and remaining issues. Curr Opin Pharmacol. 2020;55:53-59. PMID: 33128934
- [2] Kim YH, Martson AG, Dreesen E, Spriet I, Wicha SG, McLachlan AJ, Alffenaar JW. Saliva for precision dosing of antifungal drugs: Saliva population PK model for voriconazole based on a systematic review. Front Pharmacol. 2020;11:894. PMID: 32595511
- [3] \* Dreesen E, Berends S, Laharie D, D'Haens G, Vermeire S, Gils A, Mathôt R. Modelling of the Relationship Between Infliximab Exposure, Faecal Calprotectin, and Endoscopic Remission in Patients with Crohn's Disease. Br J Clin Pharmacol. 2020. PMID: 32415677
- [4] \* Kantasiripitak W, Van Daele R, Gijssen M, Ferrante M, Spriet I, Dreesen E. Software Tools for Model-Informed Precision Dosing: How Well do They Satisfy the Needs? Front Pharmacol. 2020;11:620. PMID: 32457619
- [5] Bossuyt P, Dreesen E, Rimola J, Devuysere S, De Bruecker Y, Vanslambrouck R, Laurent V, Zappa M, Savoye-Collet C, Pariente B, Filippi J, Baert F, D'haens G, Laharie D, Peyrin-Biroulet L, Vermeire S on behalf of the Tailorix study group. Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2020;S1542-3565(20)30597-8. PMID: 32360982
- [6] Dreesen E, D'Haens G, Laharie D, Vermeire S. Reply. Clin Gastroenterol Hepatol. 2020;S1542-3565(20)30326-8. PMID: 32200086
- [7] Hanžel J, Zdovc J, Kurent T, Sever N, Javornik K, Tuta K, Koželj M, Smrekar N, Novak G, Štabuc B, Dreesen E, Thomas D, Vovk T, Grabnar I, Drobne D. Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission. Clin Gastroenterol Hepatol. 2020;S1542-3565(20)30203-2. PMID: 32109630
- [8] Vermeire S, Dreesen E, Papamichael K, Dubinsky MC. How, When, and for Whom Should We Perform Therapeutic Drug Monitoring? Clin Gastroenterol Hepatol. 2020;18(6):1291-1299. PMID: 31589978

- [9] Verstockt B, Mertens E, Dreesen E, Outtier A, Noman M, Tops S, Schops G, Van Assche G, Vermeire S, Gils A, Ferrante M. Influence of drug exposure on vedolizumab-induced endoscopic remission in anti-TNF naïve and anti-TNF exposed IBD patients. *J Crohns Colitis*. 2019;14(3):332-341. PMID: 31504343
- [10] \* Dreesen E, Kantasiripitak W, Detrez I, Stefanović S, Vermeire S, Ferrante M, Bouillon T, Drobne D, Gils A. A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis. *Inflamm Bowel Dis*. 2019;26(4):570-580. PMID: 31372650
- [11] Dreesen E, Gils A. Reply. *Clin Gastroenterol Hepatol*. 2020;18(1):262-263. PMID: 31254674
- [12] \* Dreesen E, Baert F, Laharie D, Bossuyt P, Bouhnik Y, Buisson A, Lambrecht G, Louis E, Oldenburg B, Pariente B, Pierik M, van der Woude CJ, D'Haens G, Vermeire S, Gils A. Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease. *Clin Gastroenterol Hepatol*. 2019;18(3):637-646.e11. PMID: 31128336
- [13] Dreesen E, Gils A. Pharmacodynamic Monitoring of Biological Therapies in Chronic Inflammatory Diseases. *Ther Drug Monit*. 2019;41(2):131-141. PMID: 30883507
- [14] Vande Casteele N, Baert F, Bian S, Dreesen E, Compernelle G, Van Assche G, Ferrante M, Vermeire S, Gils A. Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study. *J Crohns Colitis*. 2019;13(10):1248-1256. PMID: 30820530
- [15] Verstockt B, Dreesen E, Noman M, Outtier A, Van den Berghe N, Aerden I, Compernelle G, Van Assche G, Gils A, Vermeire S, Ferrante M. Ustekinumab exposure-outcome analysis in Crohn's disease only in part explains limited endoscopic remission rates. *J Crohns Colitis*. 2019;13(7):864-872. PMID: 30715258
- [16] \* Dreesen E, Faelens R, Van Assche G, Ferrante M, Vermeire S, Gils A, Bouillon T. Optimising infliximab induction dosing for patients with ulcerative colitis. *Br J Clin Pharmacol*. 2019;85(4):782-795. PMID: 30634202
- [17] van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, Vermeire S. Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease. *J Pediatr Gastroenterol Nutr*. 2019;68(6):847-853. PMID: 30633108
- [18] van Hoeve K, Dreesen E, Hoffman I, van Assche G, Ferrante M, Gils A, Vermeire S. Efficacy, pharmacokinetics and immunogenicity is not affected by switching from infliximab originator to a biosimilar in pediatric patients with inflammatory bowel disease. *Ther Drug Monit*. 2019;41(3):317-324. PMID: 30633088
- [19] Dreesen E, Gils A. Letter: overcoming secondary loss of response to infliximab - it's not the drug, it's how you use it! Authors' reply. *Aliment Pharmacol Ther*. 2018;48(9):1029-1030. PMID: 30318686
- [20] Dreesen E, Gils A. Pharmacodynamic Monitoring of Biological Therapies in Chronic Inflammatory Diseases. *Ther Drug Monit*. 2018;41(2):131-141. PMID: 30299428
- [21] van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, Vermeire S. Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease. *J Crohns Colitis*. 2018;12(11):1316-1325. PMID: 30239644
- [22] Dreesen E, Verstockt B, Bian S, de Bruyn M, Compernelle G, Tops S, Noman M, Van Assche G, Ferrante M, Gils A, Vermeire S. Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol*. 2018;16(12):1937-1946.e8. PMID: 29704680
- [23] Strik AS, Dreesen E, Samaan M, Gecse K, Matheeuwsen M, Berends S, D'Haens G. Effectiveness and safety of switching IBD patients from the originator to the biosimilar infliximab. *Cochrane Database of Systematic Reviews*; 2018; Vol. 2018; iss. 7
- [24] Dreesen E, Van Stappen T, Ballet V, Peeters M, Compernelle G, Tops S, Van Steen K, Van Assche G, Ferrante M, Vermeire S, Gils A. Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response. *Aliment Pharmacol Ther*. 2018;47(3):346-355. PMID: 29226370

- [25] Bian S, Dreesen E, Tang HT, Compernelle G, Peeters M, Van Assche G, Ferrante M, Vermeire S, Gils A. Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over Time. *Inflamm Bowel Dis*. 2017;23(12):2202-2208. PMID: 29140943
- [26] Dreesen E, Bossuyt P, Mulleman D, Gils A, Pascual-Salcedo D. Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. *Clin Pharmacol*. 2017;9:101-111. PMID: 29042821
- [27] Murias S, Magallares L, Albizuri F, Pascual-Salcedo D, Dreesen E, Mulleman D. Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics. *Ther Drug Monit*. 2017;39(4):370-378. PMID: 28703718
- [28] Passot C, Pouw MF, Mulleman D, Bejan-Angoulvant T, Paintaud G, Dreesen E, Ternant D. Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling. *Ther Drug Monit*. 2017;39(4):322-326. PMID: 28703717
- [29] Dreesen E, Gils A. Blocking  $\alpha 4\beta 7$  Integrin Through Vedolizumab: Necessary but not Sufficient? *J Crohns Colitis*. 2017;11(8):903-904. PMID: 28333273
- [30] Billiet T, Dreesen E, Cleynen I, Wollants WJ, Ferrante M, Van Assche G, Gils A, Vermeire S. A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease. *Am J Gastroenterol*. 2016;111(10):1438-1445. PMID: 27481307
- [31] Gils A, Van Stappen T, Dreesen E, Storme R, Vermeire S, Declerck PJ. Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples. *Inflamm Bowel Dis*. 2016;22(4):969-75. PMID: 26954707
- [32] Dreesen E, Gils A, Vermeire S. Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment. *Curr Drug Targets*. 2018;19(7):757-776. PMID: 26953243
- [33] Detrez I, Dreesen E, Van Stappen T, de Vries A, Brouwers E, Van Assche G, Vermeire S, Ferrante M, Gils A. Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis. *J Crohns Colitis*. 2016;10(5):575-81. PMID: 26738756

#### Summary statistics

Number of publications (PubMed): 33  
 Number of articles as first author (PubMed): 14  
 Number of articles as last author (PubMed): 2  
 Number of times cited (Web of Science): 360  
 h-index (Web of Science): 11

## BOOKS CHAPTERS

- [1] Dreesen E, Gils A. Neutralization of soluble tumor necrosis factor. In: Rogler G, Herfarth H, Hibi T, Nielsen OH, editors. *Anti-TNF therapy in Inflammatory Bowel Disease*. Basel: Karger; 2015.

## PARTICIPATION AT INTERNATIONAL MEETINGS

### Oral presentations (only as presenting author)

- [1] Dreesen E, Berends S, Laharie D, D'Haens G, Vermeire S, Gils A, Mathôt R. DOP14 Modelling of the relationship between infliximab exposure, faecal calprotectin, and endoscopic remission in patients with Crohn's disease. Congress of European Crohn's and Colitis Organisation (ECCO) 2020 – Vienna, Austria
- [2] Dreesen E, Baert F, Laharie D, Bossuyt P, Bouhnik Y, Buisson A, Lambrecht G, Louis E, Oldenburg B, Pariente B, Pierik M, van der Woude CJ, D'Haens G, Vermeire S, Gils A. Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn's disease. Congress of European Crohn's and Colitis Organisation (ECCO) 2019 – Copenhagen, Denmark



- [3] Dreesen E, Baert F, Laharie D, Bossuyt P, Bouhnik Y, Buisson A, Lambrecht G, Louis E, Oldenburg B, Pariente B, Pierik M, van der Woude CJ, D'Haens G, Vermeire S, Gils A. Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn's disease. Belgian Week of Gastroenterology (BWGE) 2019 – Antwerp, Belgium
- [4] Dreesen E, D'Haens G, Baert F, Pariente B, Bouhnik Y, van der Woude CJ, Moreau J, Laharie D, Vermeire S, Gils A. Infliximab exposure predicts superior endoscopic outcomes in patients with active Crohn's disease: pharmacokinetic-pharmacodynamic analysis of TAILORIX. Congress of European Crohn's and Colitis Organisation (ECCO) 2018 – Vienna, Austria
- [5] Dreesen E, Van Stappen T, Ballet V, Tops S, Compennolle G, Van Assche G, Ferrante M, Vermeire S, Gils A. Anti-infliximab antibody concentrations guide therapeutic decision-making in patients with Crohn's disease losing clinical response. Belgian Week of Gastroenterology (BWGE) 2017 – Antwerp, Belgium
- [6] Gils A, Dreesen E, Compennolle G, Peeters M, Brouwers E, Tops S, Ballet V, Noman M, Ferrante M, Van Assche G, Vermeire S. Recent anti-TNF exposure predicts lower vedolizumab trough concentrations in patients with Crohn disease. Belgian Week of Gastroenterology (BWGE) 2017 – Antwerp, Belgium
- [7] Gils A, Van Stappen T, Dreesen E, Storme R, Vermeire S, Declerck PJ. Anti-Remicade antibodies cross-react with the biosimilars Remsima and Inflectra in patients with inflammatory bowel disease. United European Gastroenterology Week (UEGW) 2015 – Barcelona, Spain

#### Chair of scientific sessions

- [1] titled 'Established and new drugs in IBD' at the United European Gastroenterology Week, 17 October 2016, 10:30 - 12:00, Room B Session Type: Free Paper Session, Vienna, Austria

#### Poster presentations (only as presenting author)

- [1] Dreesen E, Berends S, Laharie D, D'Haens G, Vermeire S, Gils A, Mathôt R. Modelling of the relationship between infliximab exposure, faecal calprotectin, and endoscopic remission in patients with Crohn's disease. Quantitative Systems Pharmacology Conference (QSPC) 2020 – Leiden, The Netherlands. (meeting cancelled due to COVID-19)
- [2] Kantasiripitak W, Verstockt B, Lobatón T, Thomas D, Gils A, Vermeire S, Ferrante M, Dreesen E. P542 The effect of age on infliximab pharmacokinetics in patients with inflammatory bowel disease. Congress of European Crohn's and Colitis Organisation (ECCO) 2020 – Vienna, Austria
- [3] Kantasiripitak W, Dreesen E, Detrez I, Stefanović S, Drobne D, Vermeire S, Ferrante M, Gils A. A population pharmacokinetic model to improve mucosal healing upon golimumab induction therapy in patients with ulcerative colitis. Congress of European Crohn's and Colitis Organisation (ECCO) 2019 – Copenhagen, Denmark
- [4] Dreesen E, Verstockt B, Vermeire S, Ferrante M, Gils A. A population pharmacokinetic model to support therapeutic drug monitoring during vedolizumab therapy. Congress of European Crohn's and Colitis Organisation (ECCO) 2019 – Copenhagen, Denmark
- [5] Dreesen E, Verstockt B, Vermeire S, Ferrante M, Gils A. A population pharmacokinetic model to support therapeutic drug monitoring during vedolizumab therapy. Belgian Week of Gastroenterology (BWGE) 2019 – Antwerp, Belgium
- [6] Dreesen E, Laharie D, Lambrecht G, Bossuyt P, Buisson A, Filippi J, Van Hoetegem P, D'Haens G, Vermeire S, Gils A. Reactive dose escalation of infliximab in patients with Crohn's disease in TAILORIX leads to improved outcomes. Digestive Disease Week (DDW) 2018 – Washington, DC, USA
- [7] Dreesen E, D'Haens G, Baert F, Pariente B, Bouhnik Y, van der Woude CJ, Moreau J, Laharie D, Vermeire S, Gils A. Infliximab exposure predicts superior endoscopic outcomes in patients with active Crohn's disease: pharmacokinetic-pharmacodynamic analysis of TAILORIX. Digestive Disease Week (DDW) 2018 – Washington, DC, USA
- [8] Dreesen E, Faelens R, Van Assche G, Ferrante M, Vermeire S, Gils A, Bouillon T. Adaptive dosing during infliximab induction therapy can improve mucosal healing rates in patients with ulcerative colitis. Digestive Disease Week (DDW) 2018 – Washington, DC, USA
- [9] Dreesen E, Faelens R, Van Assche G, Ferrante M, Vermeire S, Gils A, Bouillon T. Development of a population pharmacokinetic and pharmacodynamic model to describe the effect of



infliximab induction therapy on mucosal healing in patients with ulcerative colitis. Population Approach Group in Europe Meeting (PAGE) 2018 – Montreux, Switzerland

- [10] Dreesen E, D'Haens G, Baert F, Pariente B, Bouhnik Y, van der Woude CJ, Moreau J, Laharie D, Vermeire S, Gils A. Infliximab exposure predicts superior endoscopic outcomes in patients with active Crohn's disease: pharmacokinetic-pharmacodynamic analysis of TAILORIX. Belgian Week of Gastroenterology (BWGE) 2018 – Antwerp, Belgium.
- [11] Dreesen E, Laharie D, Lambrecht G, Bossuyt P, Buisson A, Filippi J, Van Hootegeem P, D'Haens G, Vermeire S, Gils A. Reactive dose escalation of infliximab in patients with Crohn's disease in TAILORIX leads to improved outcomes. Belgian Week of Gastroenterology (BWGE) 2018 – Antwerp, Belgium
- [12] Dreesen E, Laharie D, Lambrecht G, Bossuyt P, Buisson A, Filippi J, Van Hootegeem P, D'Haens G, Vermeire S, Gils A. Reactive dose escalation of infliximab in patients with Crohn's disease in TAILORIX leads to improved outcomes. Congress of European Crohn's and Colitis Organisation (ECCO) 2018 – Vienna, Austria
- [13] Dreesen E, Faelens R, Van Assche G, Ferrante M, Vermeire S, Gils A, Bouillon T. Adaptive dosing during infliximab induction therapy can improve mucosal healing rates in patients with ulcerative colitis. Belgian Week of Gastroenterology (BWGE) 2018 – Antwerp, Belgium.
- [14] Dreesen E, Faelens R, Van Assche G, Ferrante M, Vermeire S, Gils A, Bouillon T. Adaptive dosing during infliximab induction therapy can improve mucosal healing rates in patients with ulcerative colitis. Congress of European Crohn's and Colitis Organisation (ECCO) 2018 – Vienna, Austria
- [15] Dreesen E, Van Stappen T, Ballet V, Tops S, Compennolle G, Van Assche G, Ferrante M, Vermeire S, Gils A. Anti-Infliximab antibody concentrations guide therapeutic decision-making in patients with Crohn's disease losing clinical response. Digestive Disease Week (DDW) 2017 – Chicago, IL, USA
- [16] Dreesen E, Van Stappen T, Ballet V, Tops S, Compennolle G, Van Assche G, Ferrante M, Vermeire S, Gils A. Anti-infliximab antibody concentrations guide therapeutic decision-making in patients with Crohn's disease losing clinical response. Congress of European Crohn's and Colitis Organisation (ECCO) 2017 – Barcelona, Spain
- [17] Dreesen E, De Weerd V, Van Stappen T, Peeters E, Lobaton Ortega T, Van Assche G, Vermeire S, Gils A, Ferrante M. Higher exposure but lower response rate to infliximab induction therapy in elderly patients with inflammatory bowel disease. United European Gastroenterology Week (UEGW) 2016 – Vienna, Austria
- [18] Dreesen E, Ballet V, Compennolle G, Van Assche G, Ferrante M, Vermeire S, Gils A. Infliximab dose doubling is effective for optimizing trough concentrations and regaining clinical response in patients with Crohn's disease. United European Gastroenterology Week (UEGW) 2016 – Vienna, Austria
- [19] Dreesen E, Vande Casteele N, Tops S, Vermeire S, Gils A. Anti-drug antibodies, low serum albumin and high C-reactive protein increase infliximab clearance in patients with inflammatory bowel disease: a population pharmacokinetic study of the TAXIT trial. Population Approach Group in Europe Meeting (PAGE) 2016 – Lisbon, Portugal
- [20] Gils A, Dreesen E, Peeters M, Brouwers E, Ferrante M, Van Assche G, Vermeire S. Variability in vedolizumab exposure between patients with inflammatory bowel disease. Congress of European Crohn's and Colitis Organisation (ECCO) 2016 – Amsterdam, The Netherlands
- [21] Gils A, Storme R, Dreesen E, Van Stappen T, Declerck PJ. The biosimilars of infliximab are equally well quantified in a clinical validated infliximab assay. Congress of European Crohn's and Colitis Organisation (ECCO) 2015 – Barcelona, Spain

## RELEVANT ADDITIONAL TRAINING

- + Master of Business Administration bootcamp organised by KU Leuven, Leuven, Belgium | January – May 2020
- + Building Simulation-based Applications using R shiny and mrgsolve workshop organised by Metrum research Group, Stockholm, Sweden | June 2019
- + Getting Started with Bayesian PKPD Modeling Using Stan: Practical use of Stan and R for PKPD applications workshop organised by Metrum Research Group, Stockholm, Sweden | June 2019
- + Clinical Trial Simulation course by SGS Exprimio, Montreux, Switzerland | May 2018
- + Clinical Trial Simulation course by Prof. Dr Oscar Della Pasqua, ULLA Summer School, Leuven, Belgium | July 2017
- + Translation of mAb PKPD: Theoretical basis and Case Studies workshop organised by PIPET, Budapest, Hungary | June 2017
- + Physiological modelling of therapeutic proteins and antibody-drug conjugates workshop organised by Certara's Simcyp Division, Budapest, Hungary | June 2017
- + Research Data Management Workshop, Leuven, Belgium | January 2017
- + Advanced methods for population model building and evaluation in NONMEM for intermediate and advanced users course organised by the Uppsala Pharmacometrics Research Group, Lisbon, Portugal | June 2016
- + NONMEM Beginners Course, at Department of Pharmacology, University of Cologne, Germany | October 2015
- + Population PKPD Modeling & Simulation with the Monolix Suite and R Workshop, Crete, Greece | June 2015
- + Comprehensive Course in Pharmacokinetics: Fundamental Principles and Application to Contemporary Drug development, Leuven, Belgium | April 2015
- + Essential tools for R, Leuven Statistics Research Centre, Leuven, Belgium | September 2015
- + Nonparametric statistics, Leuven Statistics Research Centre, Leuven, Belgium | December 2014
- + Regression and analysis of variance, Leuven Statistics Research Centre, Leuven, Belgium | November 2014
- + Fundamental statistical methods, applications with SPSS, Leuven Statistics Research Centre, Leuven, Belgium | October 2014
- + Fundamental statistical methods, Leuven Statistics Research Centre, Leuven, Belgium | October 2014
- + Systematic review part I and II by Cebam – Centre for Evidence-Based Medicine, Leuven, Belgium | June 2017
- + ULLA workshop on career development, Leuven, Belgium | July 2016
- + Young GI mentoring programme by Prof. Dr Iris Dotan, Barcelona, Spain | October 2015
- + Interactive training in applied GCP for investigators & site personnel, UZ Leuven, Leuven, Belgium | September 2015
- + Training networking for doctoral researchers, KU Leuven | October 2014
- + Effective medical writing & data presentation by PharmaXL, Leuven, Belgium | September 2014